Evidence map›Paper›PMID 30761653›Full record

ArticleDrug and alcohol review2019

Trends in methamphetamine and opioid use among clients of needle-syringe programs in Queensland, Australia: 2007-2015.

Brendan Jacka, Robert Kemp, Louisa Degenhardt, Amy Peacock, Philip Clare, Raimondo Bruno, Abhilash Dev, Oluwadamisola Sotade, Briony Larance

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug and alcohol review, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Brendan JackaNational Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia.ORCID 0000-0002-5910-853X
Robert KempCommunicable Diseases Branch, Queensland Health, Brisbane, Australia.
Louisa DegenhardtNational Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia.ORCID 0000-0002-8513-2218
Amy PeacockNational Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia.
Philip ClareNational Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia.ORCID 0000-0002-2009-7386
Raimondo BrunoSchool of Medicine (Psychology), University of Tasmania, Hobart, Australia.ORCID 0000-0001-6673-833X
Abhilash DevChief Medical Officer and Healthcare Regulation Branch, Queensland Health, Brisbane, Australia.
Oluwadamisola SotadeNational Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia.
Briony LaranceNational Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia.ORCID 0000-0003-3800-7673
UNSW Sydney · AUQueensland Health · AUUniversity of Tasmania · AUUniversity of Wollongong · AU

Funding

Using existing data to understand and ameliorate risk in opioid agonist therapyR01DA044170 · NIDA · UNIVERSITY OF NEW SOUTH WALES · PI DEGENHARDT, LOUISA · 2017 to 2019
$641k
NIDA NIH HHS R01 DA044170
6 · The paper itself

Abstract

INTRODUCTION AND

aimsNeedle-syringe programs (NSP) are an underutilized source of data on drug injection trends; these data are essential for informing public health interventions. We examine trends in NSP service occasions from 2007-2015. DESIGN AND

methodsUsing standardised data from 26 NSP outlets through the Queensland NSP Minimum Data Set (QNSPMDS), trends in service occasions among clients intending to inject methamphetamine, heroin, opioid substitution therapy (OST) medications and other pharmaceutical opioids were assessed using multilevel mixed-effects negative binomial regression, adjusting for month, year, age and clustering by site.

resultsOver 1.5 million service occasions were recorded in 2007-2015. Methamphetamine was the main 'drug intended to inject' (33.7%), however cf. 2007, the incidence rate ratio decreased to 0.64 (95% CI: 0.62, 0.66) in 2009, remaining low until 2015. Among clients reporting methamphetamine injection, there was a shift in the form from base to the higher-potency crystal methamphetamine since 2012. Heroin injection (22.5% service occasions) initially increased (cf. 2007), followed by a decline to 0.77 (95% CI: 0.75, 0.79) in 2015. Significant and sustained increases in OST and other pharmaceutical opioids injection were observed throughout the study period, accounting for 7.2% and 19.8% of total visits, respectively. DISCUSSION AND

conclusionsThe QNSPMDS provides unique, routinely collected, jurisdiction-wide and standardised data on the demographics of people who inject drugs, types of drugs injected and regional variations; these data are essential in informing policy, planning and program implementation. There remains significant opportunity to enhance engagement and linkage to care alongside needle-syringe provision.

Indexed as

Needle-Exchange ProgramsAdultAnalgesics, OpioidFemaleHumansMaleMethamphetamineOpiate Substitution TreatmentQueenslandSubstance Abuse, IntravenousAnalgesics, OpioidMethamphetaminecrystal methamphetamineneedle and syringe programopioid substitution therapypeople who inject drugspharmaceutical opioids

Identifiers

PMID30761653
PMCPMC6989101
OpenAlexW2913048683

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.